Sandu Pharmaceuticals Ltd.

BSE: SANDUPHQ524703ISIN INE751D01014

Healthcare
Pharmaceuticals

Share price

₹35.23-0.70 (-1.95%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹50.00
52W low: ₹30.00
Off 52W high: -29.54%
1M return: -5.47%
3M return: -11.48%
6M return: -15.92%
1Y return: -20.38%
20D avg volume: 2,490
50 DMA: ₹36.52
200 DMA: ₹37.91

Key ratios Consolidated

Market cap: ₹34.04 Cr
Current price: ₹35.23
52W high / low: ₹50.00 / ₹30.00
Face value: ₹10.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: 5.20%
Operating margin: —
Net margin: —
Debt / equity: 0.01
Net debt: ₹-0.82 Cr
Interest cover: 22.60
Dividend yield: 2.84%
Dividend / share (TTM): ₹1.00
Payout: —
Cash conversion cycle: 78.4 days

Financials

Metric	Q4 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	14.07	17.70	17.05	—
	0.07	0.03	0.04	—
	14.14	17.73	17.09	—
	13.80	17.00	16.82	—
	3.02	2.44	2.27	—
	7.29	5.41	3.94	—
	2.83	2.61	2.33	—
	0.03	0.03	0.02	—
	0.15	0.17	0.16	—
	5.02	6.03	5.01	—
	0.34	0.74	0.27	—
	0.00	0.00	0.00	—
	0.34	0.74	0.27	—
	0.02	0.24	0.10	—
	0.33	0.49	0.17	—
	0.34	0.52	0.17	—
Key metrics
	0.52	0.94	0.45	—
	3.70%	5.30%	2.60%	—
	2.30%	2.80%	1.00%	—
	0.80%	—	—	—

Metric	FY25	FY24
Income statement
	67.19	—
	0.17	—
	67.36	—
	65.20	—
	10.12	—
	23.18	—
	10.92	—
	0.10	—
	0.67	—
	21.41	—
	2.16	—
	0.00	—
	2.16	—
	0.61	—
	1.55	—
	1.60	—
Key metrics
	2.93	—
	4.40%	—
	2.30%	—
	5.20%	—
	0.01	—
	0.61	—
	0.01	—
	-0.82	—
	78.4	—
Balance sheet
	55.72	—
	26.30	—
	1.30	—
	4.76	—
	14.15	—
	8.47	—
	4.49	—
	12.09	—
	0.48	—
	0.06	—
	0.42	—
	42.02	—
Cash flow
	0.95	—
	-0.19	—
	-0.46	—
	0.94	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	16.39	16.85	18.76	17.62	16.70	14.07	18.37	17.70	17.05	—
	0.02	0.37	0.01	0.05	0.02	0.07	0.03	0.03	0.04	—
	16.41	17.22	18.77	17.67	16.72	14.14	18.40	17.73	17.09	—
	16.05	16.47	17.92	16.95	16.38	13.80	17.60	16.99	16.82	—
	2.34	3.84	2.81	2.45	1.91	3.01	2.39	2.44	2.27	—
	4.43	3.52	3.50	5.88	3.59	7.29	6.55	5.41	3.94	—
	2.79	2.74	2.65	2.64	2.66	2.83	3.16	2.61	2.33	—
	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.02	—
	0.16	0.16	0.17	0.17	0.18	0.15	0.19	0.17	0.16	—
	6.52	7.01	7.19	5.79	4.68	5.02	5.36	6.02	5.01	—
	0.36	0.75	0.85	0.71	0.34	0.34	0.80	0.74	0.27	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.36	0.75	0.85	0.71	0.34	0.34	0.80	0.74	0.27	—
	0.13	0.70	0.12	0.19	0.12	0.02	0.24	0.24	0.10	—
	0.23	0.04	0.98	0.52	0.22	0.33	0.56	0.50	0.17	—
	0.37	0.04	1.01	0.54	0.23	0.34	0.57	0.52	0.17	—
Key metrics
	0.55	0.94	1.05	0.91	0.55	0.52	1.02	0.94	0.45	—
	3.40%	5.60%	5.60%	5.20%	3.30%	3.70%	5.60%	5.30%	2.60%	—
	1.40%	0.20%	5.20%	3.00%	1.30%	2.30%	3.00%	2.80%	1.00%	—
	—	1.70%	—	1.70%	—	0.80%	—	—	—	—
	-1.90%	19.80%	2.10%	-0.50%	-2.10%	—	—	—	—	—
	4.50%	-87.90%	75.00%	4.00%	29.40%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	69.62	69.94	67.19	—
	0.45	0.44	0.17	—
	70.07	70.38	67.36	—
	67.39	67.72	65.20	—
	11.44	11.01	10.12	—
	17.33	16.48	23.18	—
	10.82	10.69	10.92	—
	0.12	0.11	0.10	—
	0.66	0.68	0.67	—
	26.51	24.67	21.41	—
	2.67	2.66	2.16	—
	0.00	0.00	0.00	—
	2.67	2.66	2.16	—
	1.14	0.89	0.61	—
	1.77	1.77	1.55	—
	1.96	1.83	1.60	—
Key metrics
	3.45	3.45	2.93	—
	4.96%	4.90%	4.40%	—
	2.54%	2.50%	2.30%	—
	—	6.10%	5.20%	—
	4.16%	4.10%	—	—
	9.94%	14.20%	—	—
	—	5.40	0.01	—
	—	3.46	0.61	—
	—	0.01	0.00	—
	—	-5.49	-1.24	—
	—	59.5	78.4	—
Balance sheet
	—	55.87	55.72	—
	—	25.32	26.30	—
	—	5.91	1.30	—
	—	5.41	4.76	—
	—	10.47	14.15	—
	—	2.58	4.74	—
	—	8.68	8.47	—
	—	4.47	4.49	—
	—	10.42	12.09	—
	—	0.42	0.06	—
	—	0.11	0.06	—
	—	0.31	0.00	—
	—	43.67	42.02	—
Cash flow
	—	6.12	0.95	—
	—	-0.57	-0.18	—
	—	-0.94	-0.46	—
	—	0.72	0.94	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +4.16%
Profit YoY (TTM): +9.94%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 37.78%

Quarter	September 2026	June 2026
Promoter %	37.78%	37.78%

Holder	Type	Holding	Previous	Change
UMESH BHASKAR SANDU	Promoter	14.37%	14.37%	0.00%
SHASHANK BHASKAR SANDU	Promoter	14.17%	14.17%	0.00%
JAYSHREE BHASKAR SANDU	Promoter	7.63%	7.63%	0.00%
SANMARK REALTY AND FINANCE PRIVATE LIMITED	Public	5.63%	5.63%	0.00%
AKSHATH FINVEST AND PROPERTIES PRIVATE LIMITED	Public	5.12%	5.12%	0.00%
NEELAMBER LEASING AND FINVEST PRIVATE LIMITED	Public	4.71%	4.71%	0.00%
TANVI JIGNESH MEHTA	Public	4.30%	4.61%	-0.31%
SANBRO MARKETING SERVICES PVT LTD	Public	2.59%	2.59%	0.00%
NOUMURA REALTY AND CONSTRUCTIONS PRIVATE LIMITED	Public	2.27%	2.27%	0.00%
PHYBRICHEM ENGINEERS PRIVATE LIMITED	Public	1.61%	1.61%	0.00%
HITESH KUVELKAR	Public	1.26%	1.26%	0.00%
GEETA U SANDU	Promoter	0.88%	0.88%	0.00%
MINAL SHASHANK SANDU	Promoter	0.63%	0.63%	0.00%
SHUBHADA PRABHAKAR SANDU	Promoter	0.10%	0.10%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Sandu Pharmaceuticals Ltd. S	34	35.23	19.25	6.10%	+4.16% TTM	+9.94% TTM	-20.38%

Filings & corporate actions

Recent announcements

Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Approval of Unaudited ....4 Nov 2026 · Board Meeting / Board Meeting
Intimation about change in name of Director from Dr Neeti Madan Kapre to Dr Neeti Gupta9 Oct 2026 · Company Update / General
compliance certificate under Reg 74(5) of SEBI(DP) Regulation for Q ended 30th September 20268 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation to the holders of Physical Securities to furnish PAN and KYC details30 Sep 2026 · Company Update / General
Intimation about closure of trading window for Quarter ended 30th September 202622 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
1. Redesignation of shri Balram Viswanathan (DIN :10245195)as Chairman and Managing Director of the company. 2.Appointment of Dr Smt Neeti Kapre (DIN:06801264)as Non Executive Independent Director12 Sep 2026 · Company Update / Change in Directorate
Appointment of M/s Dave & Dave Chartered Accountant as Statutory Auditor of the Company approved by shareholders in 41st Annual General Meeting12 Sep 2026 · Company Update / Appointment of Statutory Auditor/s
41st Annual General Meeting scrutinizers Report12 Sep 2026 · AGM/EGM / AGM
Proceedings of the 41st Annual General Meeting held on Friday 11th september 2026 at 04:30 pm11 Sep 2026 · AGM/EGM / AGM
Newspaper Publication opening of special window for re-lodgement of transfer request for physical shares4 Sep 2026 · Company Update / Newspaper Publication
Newspaper Advertisement intimating shareholders about Notice of Annual General Meeting and Evoting20 Aug 2026 · Company Update / Newspaper Publication
Letters to shareholders on annual report weblink whose email ids are not registered with the company/RTA19 Aug 2026 · Company Update / General
41st Annual Report of Sandu Pharmaceuticals Limited19 Aug 2026 · Others / Reg. 34 (1) Annual Report
Intimation about Annual General Meeting19 Aug 2026 · AGM/EGM / AGM
Newspaper Advertisement Pre despatch of Annual Report intimation to Shareholders14 Aug 2026 · Company Update / Newspaper Publication
Newspaper Publication Unaudited Financials for Q ended 30th June 202613 Aug 2026 · Company Update / Newspaper Publication
approval of material related party transactions subject to approval of shareholder11 Aug 2026 · Company Update / General
statement of deviation and utlisation of funds for q ended 30.06.202611 Aug 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Appointment of M/s Dave & Dave Chartered Accountant as statutory auditor subject to approval of the shareholder11 Aug 2026 · Company Update / Change in Management
Intimation about the date of the annual General Meeting11 Aug 2026 · Company Update / General
Intimation about the Record date11 Aug 2026 · Corp. Action / Record Date
Intimation about Book closure for AGM11 Aug 2026 · Corp. Action / Book Closure
Outcome and results of the Board Meeting dated 11.08.202611 Aug 2026 · Company Update / General
Unaudited Financials For ended 30.06.202611 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting 11.08.202611 Aug 2026 · Company Update / General
Outcome of the Board Meeting11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve 1.To consider and approve ....3 Aug 2026 · Board Meeting / Board Meeting
Reconstitution of Committees of Board-Audit/Nomination/Stakeholders11 Jul 2026 · Company Update / General
1.Appointment of Dr Neeti Madan Kapre (DIN:06801264) as additional Non Executive Independent Director of the Company 2.Redesignation of Shri Balram Viswanathan (DIN: 10245195) as Chairman ....11 Jul 2026 · Company Update / Change in Directorate
Outcome of the Board Meeting dated 11.07.202611 Jul 2026 · Board Meeting / Outcome of Board Meeting
newspaper publication-opening of special window for relodgment of special window for transfer of shares and second 100 days campaign saksham niveshak8 Jul 2026 · Company Update / Newspaper Publication
Certificate under Regulation 74(5) of SEBI(DP) Regulation7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/07/2026 ,inter alia, to consider and approve 1. To place on record ....6 Jul 2026 · Board Meeting / Board Meeting
intimation about closure of trading window for q ended 30th June 202624 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
demise of Shri Umesh Sandu, Managing Director (DIN:01132141) revised disclosure20 Jun 2026 · Company Update / General
Sad demise of Shri Umesh Sandu (DIN:01132141) Managing Director of the company19 Jun 2026 · Company Update / Change in Directorate
sad demise of Shri Umesh Sandu as Managing Director(DIN:01132141)19 Jun 2026 · Company Update / Cessation
Intimation about sad demise of our Managing Director ,Shri Umesh Sandu(DIN:01132141)19 Jun 2026 · Company Update / Demise
Newspaper Publication for opening of special window for re lodgment of transfer requests for physical shares and Second 100 days campaign Saksham Niveshak creating awareness amongst ....6 Jun 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance Report for Year ended 31st March 202618 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	4 Sep 2026	4 Sep 2026	—
Final Dividend - Rs. - 0.8000	18 Sep 2025	18 Sep 2025	—
Final Dividend - Rs. - 0.8000	19 Sep 2024	—	—

Board meetings

11 Aug 2026 Board Meeting - Financial Results